跳至主要内容
临床试验/NCT02339454
NCT02339454已完成3 期

Efficacy of Extracorporeal Shockwave Myocardial Revascularization Therapy in Patients With Stable Angina Pectoris - A Randomized, Double Blind, Placebo Controlled, Multicenter Study

Evgeny Shkolnik, MD3 个研究点 分布在 2 个国家目标入组 72 人开始时间: 2012年5月1日最近更新:
适应症
干预措施

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
72
试验地点
3
主要终点
Change in Total Exercise duration

研究概览

简要总结

Low intensity shockwaves have been proven in animal and pilot clinical studies to induce local growth of new blood vessels. Small single-center clinical trials with shockwave therapy showed promising results in reducing angina symptoms, improving perfusion and contractility in patients with refractory angina and stress-induced ischemia on imaging test.

The hypothesis of this study is that shockwave therapy could improve angina symptoms and exercise tolerance in broader population of patients with stable angina regardless of imaging test results Study aims to demonstrate anti-anginal efficacy of Extracorporeal Shockwave Myocardial Revascularization Therapy (ESMR), on top of stable optimal medical treatment in patients with stable angina.

详细描述

Low intensity shockwaves (0.09 millijoule/mm2) are delivered to myocardial tissue. Shockwaves are created by a special generator and are focused using a shockwave applicator device. The treatment is guided by standard echocardiography equipment. The shockwaves are delivered in synchronization with Patient R-wave (ECG) to avoid arrhythmias. The treatment is painless.

At first, the patient undergoes modified Bruce treadmill test, to assess exercise induced ischemia.

Exercise induced ECG ischemia is defined as the new development of horizontal or down - sloping ST segment depression (≥1 mm at 60 ms after J point) versus baseline tracing.

Study treatment consists of 9 sessions, with 3 sessions per week 1, 5 and 9. 100 shocks are delivered per spot, 1200 shocks per session.

During 1st treatment week ESMR will be delivered 3 times (every other day) to basal segments (2 spots in each wall in apical 4-, 2-, 3- chamber positions).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male and female patients (females of childbearing potential must be using adequate contraceptive precautions such as implants, injectables, combined oral contraceptives, intrauterine devices, sexual abstinence or vasectomized partner).
  • Patients aged ≥ 18 years.
  • Patients with coronary artery disease confirmed by angiography, prior MI, prior revascularization (PCI, CABG) and with exercise angina not controlled by the optimal medical therapy.
  • Patient should be on a stable dosage of medication used to treat angina for at least 4 weeks prior to enrollment.
  • ST-segment depression ≥ 1mm during exercise ECG.
  • Able and willing to sign informed consent and to comply with study procedures.
  • Written informed consent prior to enrolment into the study.

排除标准

  • Angina at rest.
  • ECG abnormalities at rest (left bundle-branch block, resting ST-segment depression ≥ 1mm, digoxin therapy, WPW-syndrome).
  • Planned coronary intervention or CABG within 6 months.
  • Heart failure (class III or IV NYHA).
  • Moderate-severe hypertension (SBP>160 mmHg and/or DBP>100 mmHg).
  • Hypotension (SBP<100 mmHg).
  • Acute coronary syndrome or coronary revascularization procedure within the prior 3 months before enrolment.
  • Females who are pregnant or nursing.
  • Any clinically relevant hematological or biochemical abnormality on routine screening, according to Investigator's judgment.
  • Severe concurrent pathology, including terminal illness (cancer, AIDS, etc.).
  • Renal impairment defined as Creatinine >150 mcmol/l.
  • Mild, moderate or severe hepatic impairment or hepatic insufficiency defined as: SGOT or SGPT > 3 times greater than normal upper limit or total serum bilirubin > 1.5 times greater than normal upper limit
  • Existing contraindications for exercise testing (e.g. acute myocarditis or pericarditis, DVT, severe aortic stenosis)
  • Dementia, psychosis, alcoholism (>350 g ethanol/week) or chronic abuse of medicines, drugs or psychoactive substances.
  • Conditions which in the Investigator's opinion may interfere with the study's execution or due to which the patient should not participate for safety reasons.
  • Risk of low patient cooperation.
  • Inability or unwillingness to issue the informed consent.
  • Patient is simultaneously participating in another device or drug study, or has participated in any clinical trial involving an experimental device or drug, including other drugs or devices enhancing cardiac neovascularization, or any cardiac shock wave therapy machine of a competitor company within 3 months of entry into the study.

研究组 & 干预措施

Active treatment group

Active Comparator

Patients in this group receive actual shockwave therapy. Study treatment consists of 9 sessions, with 3 sessions per week 1, 5 and 9. 100 shocks are delivered per spot, 1200 shocks per session.

During 1st treatment week ESMR will be delivered 3 times (every other day) to basal segments (2 spots in each wall in apical 4-, 2-, 3- chamber positions).

During 2nd treatment week ESMR will be delivered 3 times (every other day) to middle segments (2 spots in each wall in apical 4-, 2-, 3- chamber positions).

During 3rd treatment week ESMR will be delivered 3 times (every other day) to apical segments (2 spots in each wall in apical 4-, 2-, 3- chamber positions).

干预措施: Active treatment group (Device)

Placebo group

Placebo Comparator

This group of patients undergoes the same procedure as the treatment group; however shockwaves are not delivered to the heart.

干预措施: Placebo group (Device)

结局指标

主要结局

Change in Total Exercise duration

时间窗: 6 months

To evaluate if ESMR able to improve total exercise duration in modified Bruce treadmill test. Patients will be assessed at baseline visit (screening) and 6 months after the first treatment.

次要结局

  • Number of angina attacks per week(6 months)
  • Number of sublingual nitroglycerin consumption per week(6 months)
  • Seattle angina questionnaire score(6 months)
  • Time to angina in modified Bruce treadmill test(6 months)
  • Time to 1 mm ST-segment depression in modified Bruce treadmill test(6 months)
  • CCS angina functional class(6 months)

研究者

发起方
Evgeny Shkolnik, MD
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Evgeny Shkolnik, MD

Professor, department of functional methods in internal medicine

Moscow State University of Medicine and Dentistry

研究点 (3)

Loading locations...

相似试验